From: The role of insurance providers in supporting treatment and management of hepatitis C patients
Country/Reference | Direct costs | Indirect costs | Cumulative cost | Lifetime cost |
---|---|---|---|---|
USA [9] |  |  | $6.5 ($4.3–8.4) billion, increasing to $9.1 ($6.4–13.3) billion in 2024 | $64,490 |
Canada [10] | 56–81% (due to cirrhosis and its complications) | 19–44% |  | $64,694 |
Germany [11] | Mean total cost per patient for hepatic complications €556–1425, for extra-hepatic complications €1921-3547, for chronic HCV €116–577, for non-chronic HCV-related pharmacy costs €1479–3719 |  | Mean total cost per patient €5430-10,108 |  |
Belgium [12] | €126 million (€30–257 million) |  | €1850 million |  |
France [13] | 84% (47% due to liver cirrhosis, 18% to hepatocarcinoma and 19% to liver transplantation) | 16% | €65,956,938 |  |
Spain [14] | 71.5% | 28.5% | Mean total cost per patient €3198 |  |
UK [15] |  |  |  | £97,555–125,359 for disability, £26,424–32,235 for healthcare |
Ireland [16] |  |  | Mean total cost per patient €38,286–62,457 (interferon-based regimen), €55,734–81,873 (interferon-free regimen) |  |
Italy [17] | 39.4% | 60.6% | €1.06 billion |  |
Iran [18] | Total annual cost per patient USD1625.50, USD6,117.2, and USD11,047.2 for chronic HCV, cirrhosis, and hepatocellular carcinoma | Â | Â | Â |
Worldwide [19] | Median cost of liver transplantation $139,070 ($15,430-443,700), refractory ascites $16,740 ($8990-35,940), hepatocellular carcinoma $15,310 ($3370-84,710), decompensated cirrhosis $14,660 ($3810-48,360), variceal hemorrhage $12,190 ($3550-46,120), hepatic encephalopathy $9180 ($5370-50,120), diuretic sensitive ascites $3400 ($1320-7470), compensated cirrhosis $820 ($50–2890), and chronic hepatitis C $280 ($90–1860). |  |  |  |